$QLGN
Qualigen Therapeutics, Inc. Stock $qlgn

$qlgn Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000149315223041230 Filed on November 14, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q3
Revenue	$0.00	$0.00	$1.441M
YoY Change	-100.0%	-100.0%	24.76%
Cost Of Revenue			$91.00K
YoY Change			-90.84%
Gross Profit			$1.350M
YoY Change			733.63%
Gross Profit Margin			93.69%
Selling, General & Admin	$962.8K	$1.337M	$2.858M
YoY Change	-67.09%	-53.23%	-0.99%
% of Gross Profit			211.69%
Research & Development	$1.311M	$1.442M	$1.688M
YoY Change	-26.26%	-14.6%	-18.97%
% of Gross Profit			125.04%
Depreciation & Amortization	$4.500K	-$120.0K	$24.00K
YoY Change	-91.49%	-600.0%	-16.26%
% of Gross Profit			1.78%
Operating Expenses	$2.274M	$2.778M	$5.824M
YoY Change	-51.65%	-52.29%	17.19%
Operating Profit		-$2.778M	-$4.383M
YoY Change		-36.61%	-8.84%
Interest Expense	-$235.8K	-$367.3K	$4.630K
YoY Change	456.02%	-8032.18%	-31.91%
% of Operating Profit
Other Income/Expense, Net	$663.1K	-$456.7K	$327.1K
YoY Change	-693.03%	-239.62%	-81.47%
Pretax Income	-$2.472M	-$3.235M	-$4.056M
YoY Change	-71.91%	-20.24%	33.57%
Income Tax	-$4.790K
% Of Pretax Income
Net Earnings	-$2.450M	-$3.695M	-$3.825M
YoY Change	-61.55%	-3.4%	25.93%
Net Earnings / Revenue			-265.44%
Basic Earnings Per Share			-$0.10
Diluted Earnings Per Share	-$0.47	-$0.72	-$1.028M
COMMON SHARES
Basic Shares Outstanding	5.181M shares	5.052M shares	38.80M shares
Diluted Shares Outstanding		5.052M shares	3.944M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$401.8K	$2.074M	$6.618M
YoY Change	-94.29%	-68.66%	-46.28%
Cash & Equivalents	$401.8K	$2.074M	$6.624M
Short-Term Investments
Other Short-Term Assets	$765.0K	$1.376M	$1.692M
YoY Change	5958.61%	-18.71%	5.68%
Inventory			$1.482M
Prepaid Expenses
Receivables	$538.6K		$603.3K
Other Receivables			$0.00
Total Short-Term Assets	$1.167M	$3.450M	$10.40M
YoY Change	-89.22%	-66.82%	-33.93%
LONG-TERM ASSETS
Property, Plant & Equipment	$0.00		$311.5K
YoY Change	-100.0%		-34.52%
Goodwill			$4.896M
YoY Change
Intangibles			$5.852M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$866.5K	$866.5K	$18.33K
YoY Change	4626.08%	4626.09%	0.02%
Total Long-Term Assets	$866.5K	$866.5K	$12.56M
YoY Change	-89.51%	-93.1%	1770.44%
TOTAL ASSETS
Total Short-Term Assets	$1.167M	$3.450M	$10.40M
Total Long-Term Assets	$866.5K	$866.5K	$12.56M
Total Assets	$2.033M	$4.316M	$22.96M
YoY Change	-89.35%	-81.2%	39.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.223M	$1.572M	$596.0K
YoY Change	159.3%	163.71%	-34.41%
Accrued Expenses	$527.0K	$1.144M	$1.471M
YoY Change	-65.14%	-22.23%	-27.32%
Deferred Revenue
YoY Change
Short-Term Debt	$1.299M	$0.00	$941.3K
YoY Change	36.66%	-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.137M	$5.957M	$4.881M
YoY Change	-51.94%	22.03%	-10.06%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities			$1.426M
YoY Change			984.48%
Total Long-Term Liabilities	$0.00	$0.00	$1.426M
YoY Change	-100.0%	-100.0%	984.48%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.137M	$5.957M	$4.881M
Total Long-Term Liabilities	$0.00	$0.00	$1.426M
Total Liabilities	$4.137M	$5.957M	$7.043M
YoY Change	-59.9%	-15.43%	26.71%
SHAREHOLDERS EQUITY
Retained Earnings	-$116.8M	-$114.4M	-$97.00M
YoY Change	12.96%	17.94%
Common Stock	$43.26K	$42.95K	$42.11K
YoY Change	2.74%	2.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$2.104M	-$1.641M	$12.15M
YoY Change
Total Liabilities & Shareholders Equity	$2.033M	$4.316M	$22.96M
YoY Change	-89.35%	-81.2%	39.95%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q3
OPERATING ACTIVITIES
Net Income	-$2.450M	-$3.695M	-$3.825M
YoY Change	-61.55%	-3.4%	25.93%
Depreciation, Depletion And Amortization	$4.500K	-$120.0K	$24.00K
YoY Change	-91.49%	-600.0%	-16.26%
Cash From Operating Activities	-$5.672M	$927.3K	-$3.182M
YoY Change	153.45%	-129.14%	4.94%
INVESTING ACTIVITIES
Capital Expenditures			-$11.26K
YoY Change			16.44%
Acquisitions
YoY Change
Other Investing Activities	$235.4K	$3.981M	$0.00
YoY Change
Cash From Investing Activities	$235.4K	$4.231M	-$11.26K
YoY Change	-196.33%	-37671.4%	16.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-110.0K	-440.0K	3.310K
YoY Change	-103.79%	-13393.05%	-97.44%
NET CHANGE
Cash From Operating Activities	-5.672M	927.3K	-3.182M
Cash From Investing Activities	235.4K	4.231M	-11.26K
Cash From Financing Activities	-110.0K	-440.0K	3.310K
Net Change In Cash	-5.546M	4.718M	-3.190M
YoY Change	-1416.6%	-247.9%	9.52%
FREE CASH FLOW
Cash From Operating Activities	-$5.672M	$927.3K	-$3.182M
Capital Expenditures			-$11.26K
Free Cash Flow			-$3.171M
YoY Change			4.9%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Central Index Key EntityCentralIndexKey	0001460702
CY2023Q3	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent		usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet		usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent		usd
CY2023Q3	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent		usd
CY2023Q3	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent		usd
CY2023Q3	us-gaap	Disposal Group Including Discontinued Operation Other Noncurrent Liabilities DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities		usd
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax		usd
CY2023Q3	us-gaap	Minority Interest MinorityInterest		usd
CY2023Q3	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense		usd
CY2022Q3	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense		usd
	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense		usd
CY2022Q3	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets		usd
	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets		usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q3	us-gaap	Discontinued Operation Tax Effect Of Income Loss From Disposal Of Discontinued Operation DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation		usd
	us-gaap	Discontinued Operation Tax Effect Of Income Loss From Disposal Of Discontinued Operation DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation		usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax		usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization		usd
	QLGN	Loss On Voluntary Conversion Of Convertible Debt LossOnVoluntaryConversionOfConvertibleDebt		usd
	QLGN	Accretion Of Discount On Convertible Debt AccretionOfDiscountOnConvertibleDebt		usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1		usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		usd
	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations		usd
	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations		usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	QLGN	Transfers Of Inventory From Equipment Held For Lease TransfersOfInventoryFromEquipmentHeldForLease		usd
	QLGN	Fair Value Of Warrant Liabilities On Date Of Exercise FairValueOfWarrantLiabilitiesOnDateOfExercise		usd
	QLGN	Voluntary Conversion Of Convertible Debt Into Common Stock VoluntaryConversionOfConvertibleDebtIntoCommonStock		usd
CY2022Q4	us-gaap	Receivable Investment Sale ReceivableInvestmentSale		usd
CY2022Q4	QLGN	Preapaid Research And Development Expenses PreapaidResearchAndDevelopmentExpenses		usd
	QLGN	Fair Value Of Warrant Liabilities On Date Of Exercise FairValueOfWarrantLiabilitiesOnDateOfExercise		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate		pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum		pure
CY2023Q3	us-gaap	Share Price SharePrice
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Registrant Name EntityRegistrantName	Qualigen Therapeutics, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity File Number EntityFileNumber	001-37428
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-3474527
	dei	Entity Address Address Line1 EntityAddressAddressLine1	5857 Owens Avenue
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 300
	dei	Entity Address City Or Town EntityAddressCityOrTown	Carlsbad
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92008
	dei	City Area Code CityAreaCode	(760)
	dei	Local Phone Number LocalPhoneNumber	452-8111
	dei	Security12b Title Security12bTitle	Common Stock, par value $.001 per share
	dei	Trading Symbol TradingSymbol	QLGN
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	5181058	shares
CY2023Q3	us-gaap	Cash Cash	2073849	usd
CY2022Q4	us-gaap	Cash Cash	3165985	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1375730	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1366704	usd
CY2022Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	6287849	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	3449579	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	10820538	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	26242	usd
CY2023Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	866481	usd
CY2022Q4	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	8236711	usd
CY2023Q3	us-gaap	Assets Assets	4316060	usd
CY2022Q4	us-gaap	Assets Assets	19083491	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1571831	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	619568	usd
CY2023Q3	us-gaap	Accrued Vacation Current AccruedVacationCurrent	163701	usd
CY2022Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	165040	usd
CY2023Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	1144188	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	699519	usd
CY2023Q3	us-gaap	Hedging Liabilities Current HedgingLiabilitiesCurrent	92900	usd
CY2022Q4	us-gaap	Hedging Liabilities Current HedgingLiabilitiesCurrent	788100	usd
CY2023Q3	QLGN	Warrant Liabilities Related Party WarrantLiabilitiesRelatedParty	2151892	usd
CY2022Q4	QLGN	Warrant Liabilities Related Party WarrantLiabilitiesRelatedParty	2834547	usd
CY2023Q3	us-gaap	Convertible Debt ConvertibleDebt	832100	usd
CY2022Q4	us-gaap	Convertible Debt ConvertibleDebt	60197	usd
CY2022Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	3441198	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	5956612	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8608169	usd
CY2022Q4	us-gaap	Disposal Group Including Discontinued Operation Other Noncurrent Liabilities DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities	1708732	usd
CY2023Q3	us-gaap	Liabilities Liabilities	5956612	usd
CY2022Q4	us-gaap	Liabilities Liabilities	10316901	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5052463	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5052463	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4210737	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4210737	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	42952	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	42110	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	112668631	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	110528050	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	50721	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-114352135	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-103385172	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-1640552	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7235709	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	1530881	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1640552	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8766590	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4316060	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	19083491	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1336765	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2539389	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5132834	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7705823	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1441598	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	930536	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3898061	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3618428	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	2778363	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	3469925	usd
	us-gaap	Operating Expenses OperatingExpenses	9030895	usd
	us-gaap	Operating Expenses OperatingExpenses	11324251	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2778363	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3469925	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9030895	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11324251	usd
CY2023Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-101112	usd
CY2022Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	321300	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1377855	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1019342	usd
CY2023Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-367257	usd
CY2022Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	4631	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1288908	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	15763	usd
	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	1077287	usd
CY2023Q3	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	-21747	usd
	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	-21747	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	33454	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	33534	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-456662	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	325931	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-976553	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1035105	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3235025	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3143994	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10007448	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10289146	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6173	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-3235025	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-3143994	usd
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-10007448	usd
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-10295319	usd
CY2023Q3	us-gaap	Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax	159507	usd
CY2022Q3	us-gaap	Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax	-911882	usd
	us-gaap	Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax	-683008	usd
	us-gaap	Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax	-2207864	usd
CY2023Q3	us-gaap	Discontinued Operation Tax Effect Of Income Loss From Disposal Of Discontinued Operation DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation	619545	usd
	us-gaap	Discontinued Operation Tax Effect Of Income Loss From Disposal Of Discontinued Operation DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation	619545	usd
CY2023Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-460038	usd
CY2022Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-911882	usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-1302553	usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-2207864	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-3695063	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-4055876	usd
	us-gaap	Profit Loss ProfitLoss	-11310001	usd
	us-gaap	Profit Loss ProfitLoss	-12503183	usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-38526	usd
CY2022Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-230767	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-343038	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-234883	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3656537	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3825109	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10966963	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12268300	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.64
CY2023Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.64
CY2022Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.80
CY2022Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.80
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-1.99
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-1.99
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-2.77
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-2.77
CY2023Q3	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare	-0.08
CY2023Q3	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	-0.08
CY2022Q3	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare	-0.17
CY2022Q3	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	-0.17
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare	-0.19
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	-0.19
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare	-0.53
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Diluted Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare	-0.53
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5052463	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5052463	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3944406	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3944406	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5021691	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5021691	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3715462	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3715462	shares
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-3695063	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-4055876	usd
	us-gaap	Profit Loss ProfitLoss	-11310001	usd
	us-gaap	Profit Loss ProfitLoss	-12503183	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	88523	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-50721	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	154063	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-3695063	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-3967353	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-11360722	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-12349120	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-38526	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-230767	usd
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-343038	usd
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-234883	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3656537	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3736586	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11017684	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12114237	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8766590	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1112582	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	252226	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest	176220	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-4107249	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6200369	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	672111	usd
CY2023Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest	-56747	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-3507689	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3308044	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	113801	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-3695063	usd
CY2023Q3	QLGN	Deconsolidation Of Discontinued Operations DeconsolidationOfDiscontinuedOperations	-1367334	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1640552	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	16564734	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	4716	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1267166	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-4319787	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	13516829	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	1844500	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1746816	usd
CY2022Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest	65540	usd
CY2022Q2	us-gaap	Noncontrolling Interest Increase From Business Combination NoncontrollingInterestIncreaseFromBusinessCombination	4000000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	696	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1423282	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-4127520	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	18470143	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	18470143	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3315	usd
CY2022Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest	88523	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1409504	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-4055876	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	15915609	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	15915609	usd
	us-gaap	Profit Loss ProfitLoss	-11310001	usd
	us-gaap	Profit Loss ProfitLoss	-12503183	usd
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-1302553	usd
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-2207864	usd
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-10007448	usd
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-10295319	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	9122	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1028841	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	4099952	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1377855	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1019342	usd
	QLGN	Loss On Voluntary Conversion Of Convertible Debt LossOnVoluntaryConversionOfConvertibleDebt	-1077287	usd
	QLGN	Accretion Of Discount On Convertible Debt AccretionOfDiscountOnConvertibleDebt	-1247198	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-21747	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	640105	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	378498	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	952269	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-291166	usd
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	443330	usd
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-728233	usd
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-7254736	usd
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-8603484	usd
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	2622059	usd
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-2406331	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4632677	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11009815	usd
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	3980541	usd
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	60612	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	3980541	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	60612	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	7173	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	440000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-440000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	7173	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-440000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7173	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1092136	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-10942030	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	27523	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3165985	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	17538272	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2073849	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6623765	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	4900	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	3501	usd
	QLGN	Transfers Of Inventory From Equipment Held For Lease TransfersOfInventoryFromEquipmentHeldForLease	83271	usd
	QLGN	Fair Value Of Warrant Liabilities On Date Of Exercise FairValueOfWarrantLiabilitiesOnDateOfExercise	858	usd
	QLGN	Voluntary Conversion Of Convertible Debt Into Common Stock VoluntaryConversionOfConvertibleDebtIntoCommonStock	1112582	usd
CY2022Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	These warrants were subsequently exercised on September 13, 2022
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_846_eus-gaap--UseOfEstimates_zH9Bc4DIGoR4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_z1QtoE9qAYdk">Accounting Estimates</span> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management uses estimates and assumptions in preparing its condensed consolidated financial statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. The most significant estimates relate to the estimated fair value of in-process research and development, goodwill, warrant liabilities, and stock-based compensation. Actual results could vary from the estimates that were used.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p>
CY2023Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2022Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2023Q3	us-gaap	Cash Cash	2100000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-114400000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4600000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11000000.0	usd
CY2023Q3	us-gaap	Cash Cash	5200000	usd
CY2023Q3	us-gaap	Share Based Compensation ShareBasedCompensation	5800000	usd
CY2023Q3	us-gaap	Cash Cash	5200000	usd
CY2023Q3	us-gaap	Escrow Deposit EscrowDeposit	450000	usd
CY2021Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8800000	usd
CY2021Q4	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	3000000.0	usd
CY2023Q3	us-gaap	Prepaid Insurance PrepaidInsurance	740770	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1329033	usd
CY2023Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	53787	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	37671	usd
CY2023Q3	us-gaap	Receivable Investment Sale ReceivableInvestmentSale	235402	usd
CY2023Q3	QLGN	Preapaid Research And Development Expenses PreapaidResearchAndDevelopmentExpenses	345771	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1375730	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1366704	usd
CY2023Q3	us-gaap	Escrow Deposit EscrowDeposit	450000	usd
CY2023Q3	QLGN	Longterm Research And Development Deposits LongtermResearchAndDevelopmentDeposits	416481	usd
CY2023Q3	us-gaap	Other Assets OtherAssets	866481	usd
CY2023Q3	QLGN	Purchase Price PurchasePrice	4700000	usd
CY2023Q3	us-gaap	Escrow Deposit EscrowDeposit	450000	usd
CY2023Q3	QLGN	Working Capital WorkingCapital	235402	usd
CY2023Q3	QLGN	Fairvalue Of Consideration Received FairvalueOfConsiderationReceived	5489337	usd
	QLGN	Fairvalue Of Consideration Received FairvalueOfConsiderationReceived	5489337	usd
CY2023Q3	QLGN	Working Capital Adjustment WorkingCapitalAdjustment	235402	usd
	QLGN	Working Capital Adjustment WorkingCapitalAdjustment	235402	usd
CY2023Q3	QLGN	Total Assets Of Discontinued Operations TotalAssetsOfDiscontinuedOperations	-4225562	usd
CY2023Q3	QLGN	Total Liabilities Ofdiscontinued Operations TotalLiabilitiesOfdiscontinuedOperations	3005407	usd
CY2023Q3	QLGN	Transaction Expenses TransactionExpenses	-645119	usd
	QLGN	Transaction Expenses TransactionExpenses	-645119	usd
CY2023Q3	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	3859465	usd
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	3859465	usd
CY2023Q3	QLGN	Accrued Compensation AccruedCompensation	40833	usd
CY2022Q4	QLGN	Accrued Compensation AccruedCompensation	70000	usd
CY2023Q3	us-gaap	Interest Payable Current InterestPayableCurrent	68322	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	2829	usd
CY2023Q3	QLGN	Accrued License Fees AccruedLicenseFees	167200	usd
CY2022Q4	QLGN	Accrued License Fees AccruedLicenseFees	150130	usd
CY2023Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	35939	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	1247	usd
CY2023Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	506080	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	136203	usd
CY2023Q3	QLGN	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	278024	usd
CY2022Q4	QLGN	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	329412	usd
CY2023Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	47790	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	9698	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1144188	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	699519	usd
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	247625	shares
CY2022Q2	us-gaap	Stock Issued During Period Shares Treasury Stock Reissued StockIssuedDuringPeriodSharesTreasuryStockReissued	346896	shares
CY2022Q4	QLGN	Fair Value Adjustment Of Warrant FairValueAdjustmentOfWarrant	3622647	usd
	QLGN	Change In Fair Value Of Warrant Liabilities ChangeInFairValueOfWarrantLiabilities	-1377855	usd
CY2023Q3	QLGN	Fair Value Adjustment Of Warrant FairValueAdjustmentOfWarrant	2244792	usd
CY2022Q4	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.08	pure
CY2023Q1	us-gaap	Common Stock Dividends Shares CommonStockDividendsShares	841726	shares
CY2023Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1.32
CY2023Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1111078	usd
CY2023Q1	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1100000	usd
CY2023Q3	us-gaap	Debt Instrument Periodic Payment Interest DebtInstrumentPeriodicPaymentInterest	368000	usd
	us-gaap	Debt Instrument Periodic Payment Interest DebtInstrumentPeriodicPaymentInterest	1300000	usd
CY2023Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	350000	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1200000	usd
CY2023Q3	QLGN	Fair Value Adjustments Of Warrant FairValueAdjustmentsOfWarrant	2200000	usd
CY2023Q3	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	0	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4476149	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1688048	shares
CY2022Q2	us-gaap	Litigation Settlement Amount Awarded To Other Party LitigationSettlementAmountAwardedToOtherParty	96558	usd
CY2023Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1111078	usd
CY2023Q1	us-gaap	Common Stock Dividends Shares CommonStockDividendsShares	841726	shares
CY2023Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1.32
CY2023Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	4476149	shares
CY2023Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	4476149	shares
CY2023Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	400000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y3M21D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.03	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2022Q3	us-gaap	Share Price SharePrice	0.52
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1022039	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4099952	usd
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	60000	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	13.20
CY2021	QLGN	Fair Value Of Issuance Cost FairValueOfIssuanceCost	300000	usd
CY2020Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	219101	shares
CY2020Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	40.70
CY2023Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	696	usd

Files In Submission

Name	View Source	Status
qlgn-20230930_pre.xml	Edgar Link	unprocessable
0001493152-23-041230-index-headers.html	Edgar Link	pending
0001493152-23-041230-index.html	Edgar Link	pending
0001493152-23-041230.txt	Edgar Link	pending
0001493152-23-041230-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
qlgn-20230930.xsd	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
qlgn-20230930_cal.xml	Edgar Link	unprocessable
qlgn-20230930_def.xml	Edgar Link	unprocessable
qlgn-20230930_lab.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$QLGN
Qualigen Therapeutics, Inc. Stock $qlgn

2023 Q4 Form 10-Q Financial Statement

#000149315223041230 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$QLGN Qualigen Therapeutics, Inc. Stock $qlgn

2023 Q4 Form 10-Q Financial Statement

#000149315223041230 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$QLGN
Qualigen Therapeutics, Inc. Stock $qlgn